GlassScriptPhysician profile
Salvatore M Nardello
NPI 1730401811
$23,015.77
in general payments reported to CMS, 2019-2025
31 companies · $8,060 in 2025
The $8,060 reported for 2025 was more than what 92% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $598 · 2021: $1,227 · 2022: $690 · 2023: $2,465 · 2024: $9,164 · 2025: $8,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,387 · Food and Beverage: $6,962 · Travel and Lodging: $4,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,387.00 |
| Food and Beverage | $6,962.17 |
| Travel and Lodging | $4,338.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molnlycke Health Care US, LLC | $8,156.11 | 2024-2025 | Biogel Pi Indicator Underglove, Biogel Pi Micro Indicator Underglove, Biogel Indicator System |
| Dilon Technologies, INC. | $4,138.52 | 2022-2025 | Hemoblast Bellows |
| Stryker Corporation | $3,993.99 | 2025 | Molli, 1788, Spy-Phi System |
| Biom'Up France Sas | $937.60 | 2020-2021 | |
| Mentor Worldwide LLC | $819.78 | 2022-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Aroa Biosurgery Incorporated | $565.54 | 2023-2025 | |
| Molli Surgical (US) INC | $500.00 | 2024 | |
| Hologic INC | $425.00 | 2024 | Trident Specimen Radiography System |
| Solventum Corporation | $391.08 | 2024-2025 | V.A.C.Ulta, Prevena, Promogran Prisma |
| Sientra, INC. | $344.14 | 2021 | |
| Biom'Up Sa | $321.62 | 2019 | |
| Kci USA, INC. | $315.96 | 2021-2023 | 3m Cavilon, Prevena Restor Bellaform, Prevena |
| Endomagnetics LTD | $294.27 | 2023 | Magtrace, Magseed |
| Elucent Medical | $201.50 | 2023 | |
| Genentech USA, INC. | $185.98 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Focal Therapeutics, INC. | $182.95 | 2019 | |
| Medtronic USA, INC. | $169.39 | 2020 | |
| Allergan, INC. | $167.41 | 2019 | |
| W. L. Gore & Associates, INC. | $161.25 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Axogen | $156.00 | 2023 | Avance Nerve Graft |
| Merit Medical Systems INC | $127.56 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $120.66 | 2023 | |
| Innovation Technologies INC | $114.83 | 2022 | |
| Ethicon US, LLC | $54.82 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $51.75 | 2024-2025 | Lynparza, Keytruda |
| Csl Behring | $28.31 | 2023 | Kcentra |
| Integra Lifesciences Corporation | $22.39 | 2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Smith+Nephew, INC. | $20.77 | 2023 | Collagenase Santyl, Regranex |
| Tei Biosciences INC | $18.05 | 2019 | |
| Leica Microsystems INC. | $14.91 | 2021 | |
| Convatec INC. | $13.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Nardello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.